To evaluate the longitudinal changes in optic disk neovascularization (NVD) after intravitreal bevacizumab injection using optical coherence tomography angiography.
In this prospective, interventional, case series, eyes with NVD secondary to diabetic retinopathy were enrolled. En face optical coherence tomography angiographic images were obtained from the optic disks before and 3 hours, 6 hours, 24 hours, 7 days, and 30 days after intravitreal bevacizumab injection. The size and flow area of the neovascularization were measured by two graders.
Eleven eyes of 9 patients with a mean age of 52.11 ± 9.48 years were included. The reduction in the NVD size and flow area was statistically significant at 24 hours, 7 days, and 30 days after injections compared with the baseline measurements (all P < 0.05). The decremental regression in the NVD size and flow area continued during the study course. The changes were not statistically significant in 3-hour and 6-hour measurements (all P > 0.05).
In this study, statistically significant regression in the NVD size and flow area was observed as early as 24 hours after a single intravitreal bevacizumab injection, with a continued decreasing trend for at least a 1-month period.
Regression in the size and flow area of the disk neovascularization was detected as early as 24 hours after a single intravitreal bevacizumab injection using optical coherence tomography angiography, with a continued decreasing trend for at least a 1-month period.
*Eye Research Center, Department of Ophthalmology, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran; and
†Department of Ophthalmology, David Geffen School of Medicine, University of California-Los Angeles, California, and Doheny Eye Institute, Los Angeles, California.
Reprint requests: Khalil Ghasemi Falavarjani, MD, Eye Research Center, Rassoul Akram Hospital, Sattarkhan-Niaiesh Street, Tehran,1445613131 Iran; e-mail: firstname.lastname@example.org
S. Sadda is a consultant for Optos, Alergan, Genentech, Novartis, Thrombogenics, Iconic, CenterVue, and NightstaRx and receives financial support from Optos, Alergan, Genentech, and Carl Zeiss Meditec. The remaining authors have no financial/conflicting interests to disclose.